Promising combo tackles tough liver cancer
NCT ID NCT03463876
First seen Feb 22, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study tested a combination of two drugs—SHR-1210 (an immunotherapy) and apatinib (a targeted therapy)—in 190 adults with advanced liver cancer that had not responded to or could not tolerate prior treatment. The goal was to see if the combo could shrink tumors and control the disease. Participants received both drugs and were monitored for response and side effects. This is not a cure, but aims to control the cancer and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Beijing, Beijing Municipality, 100071, China
Conditions
Explore the condition pages connected to this study.